Home / Companies / News /  World’s most expensive drugs can’t cure what ails this biotech

World’s most expensive drugs can’t cure what ails this biotech

wsj
In the most severe form of beta thalassemia, people undergo blood transfusions every few weeks, basically tethering them to the doctor’s office. Bluebird’s drug, Zynteglo, could be life-altering with only a single treatment (Bluebird Bio)Premium
In the most severe form of beta thalassemia, people undergo blood transfusions every few weeks, basically tethering them to the doctor’s office. Bluebird’s drug, Zynteglo, could be life-altering with only a single treatment (Bluebird Bio)

Bluebird Bio has received attention for pricing two FDA-approved gene therapies at around $3 million, but its financial future remains uncertain

Bluebird Bio is about to become the seller of the two most expensive drugs in the US, and by extension the world, each fetching nearly $3 million.

Recommended For You

Trending Stocks

×
Get alerts on WhatsApp
Set Preferences My ReadsWatchlistFeedbackRedeem a Gift CardLogout